No Detail Found!

Association of BCR-ABLalternative splice variants with disease progression, treatment response and survival in chronic myeloid leukemia patients treated with firstline imatinib monotherapy

Author(s)
Nawaf Al-anazi CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Zafar Iqbal CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia; Hematology, Oncology and Pharmaco-genetic Engineering Sciences (HOPES) Group, Health Sciences Department of Zoology, University of the Punjab, Lahore 54590 - Pakistan; Next-Generation Medical Biotechnology Division, Department of Biotechnology, University of Sialkot - Pakistan
Tanveer Akhtar CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Ahmad M. Khalid Next-Generation Medical Biotechnology Division, Department of Biotechnology, University of Sialkot - Pakistan
Aamer Aleem Division of Hematology/Oncology, Department of Medicine, KKUH and College of Medicine, King Saud University, Riyadh - Saudi Arabia
Saba Shahzadi Hematology, Oncology and Pharmaco-genetic Engineering Sciences (HOPES) Group, Health Sciences Department of Zoology, University of the Punjab, Lahore 54590 - Pakistan
Afia M. Akram Hematology, Oncology and Pharmaco-genetic Engineering Sciences (HOPES) Group, Health Sciences Department of Zoology, University of the Punjab, Lahore 54590 - Pakistan; University of Education Lahore, Pakistan
Mahmood Rasool CEGMR, King Abdulaziz University, Jeddah - Saudi Arabia
Ijaz H. Shah Allied Hospital Faisalabad – Pakistan
Muhammad Khalid Allied Hospital Faisalabad – Pakistan
Mudassar Iqbal Asian Medical Institute, Kant - Kyrgyzstan
Abid Jameel Khyber Teaching Hospital and Hayatabad Medical Complex, Peshawar - Pakistan
Zeba Aziz Department of Oncology, Hamid Latif Hospital, Lahore - Pakistan; Department of Oncology, Jinnah Hospital, Lahore - Pakistan
Muhammad Farooq Sabar Centre for Applied Molecular Biology, University of the Punjab, Lahore - Pakistan
Maryam AlMajed CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Buthinah AlShehab CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Sarah AlMukhaylid CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Nouf AlMutairi CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Dhay Almaghlouth CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Alhanoof Alsuwaidani CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia
Muhammad Arshad Department of Biological Sciences, International Islamic University, Islamabad - Pakistan
Rashid Ayub Department of Science and Technology Innovation Unit (STIU), King Saud University, Riyadh - Saudi Arabia
Khaled AlJarrah CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City/KAIMRC, National Guard Health Affairs, Al-Ahsa - Saudi Arabia; Jordan University of Science and Technology. Irbid - Jordan
Amer Mehmood Cancer Stem Cell Unit, Department of Anatomy, King Saud University, Riyadh - Saudi Arabia
Abstract
Background: Alternative RNA splicing has diverse biological effects in heath as well as disease. It also contributes to cancer onset and progression. Chronic Myeloid Leukemia (CML) results due to BCR-ABL fusion oncogene that is created due to chromosomal translocation t [9; 22] [q34; q11]). BCR-ABL is target of tyrosine kinase inhibitors (TKIs). BCR-ABL through alternative splicing can generate b2a2, b3a2 and some other rare splicing variants. BCR-ABL variants may vary in their response to TKI treatment and disease progression potential, which is a major factor contributing to dismal treatment outcome in CML. Objective: The objective of this study is to investigate correlation of BCR-ABL splice variants with TKI treatment outcome and survival in three phases of CML that has rarely been studied previously. Methods: BCR-ABL splice variants were studied using reverse transcriptase PCR (RT-PCR). in 70 CML patients from three phases of CML who were receiving imatinib (TKI) treatment. Results: Frequencies of different BCR/ABL splice variants like b3a2, b2a2 and b3a2+b2a2 were 49 (70%), 15 (21.4%) and 6 (8.6%), respectively. Splice variant b2a2 were more common (53.3%) in chronic phase CML (CP-CML) while b3a2 had higher frequency in advanced phases of CML (44.9%). CML patients with b2a2 transcript had better complete cytogenetic response and major molecular response to TKI treatment overall (100% vs. 24.5%) as well as in CP-CML (100% vs. 85.7%) and superior survival when compared to patients with b3a2 splice variant. All patients who died had male gender, less than 33 years age, b3a2 transcript, advanced phases of CML and imatinib resistance. Conclusions: Splice variant b3a2 was associated with CML progression, poorer survival and inferior treatment outcome as compared to b2a2. Further investigations on BCR-ABL splice variants and their roles in CML pathogenesis can provide deeper insights into CML biology and new targets for BCR-ABL positive leukemia treatment.
Publication Details
Page(s) 612-617
DOI DOI not available
Published Journal: Advancements in life sciences, Volume: 9, Issue: 4, Year: 2022

Request the full text from PASTIC

Keywords
survival, Treatment outcome, Progression, BCR-ABL splice variants
0

Citations

0

Downloads

58

Views